Menu

Inhibikase Therapeutics, Inc. IKT

Full chart Compare
Set alert

Price alert · IKT

All alert types
1.68 USD +0.18 (+12.00%)

At closeNov 9, 2026, 4:01 PM EST

1.68 0.00 0.00%

After hours · Nov 9, 4:01 PM ET

1.51 Day range 1.73
1.40 52-week range 2.61
YTD
-18.05%
1 year
+12.00%

Revenue & Expenses

Other Income → Expenses: $1.06MExpenses → Selling, General & Admin: $6.73MExpenses → Research & Development: $13.62MGross Profit → Expenses: $260.50KRevenue → Gross Profit: $260.50KNet Loss → Expenses: $19.03MOther Income$1.06MGross Profit$260.50KNet Loss$19.03MExpenses$20.35MSelling, General & Admin$6.73MResearch & Development$13.62MRevenue$260.50K

Latest period ending Dec 31, 2025 · select a line to chart its full history

IKT annual income statement
Fiscal yearFY 2025 Dec 31, 2025FY 2024 Dec 31, 2024FY 2023 Dec 31, 2023FY 2022 Dec 31, 2022FY 2021 Dec 31, 2021
-53.35M-28.59M-20.09M-18.13M-14.77M
-48.26M-27.52M-19.03M-18.05M-14.79M
-0.49-1.16-3.16-4.28-4.86
IKT annual balance sheet
Fiscal yearFY 2025 Dec 31, 2025FY 2024 Dec 31, 2024FY 2023 Dec 31, 2023FY 2022 Dec 31, 2022FY 2021 Dec 31, 2021
139.22M56.49M9.17M7.19M40.75M
181.20M98.60M14.51M24.94M42.47M
8.30M3.73M3.53M3.90M4.05M
172.90M94.87M10.98M21.04M38.42M
IKT annual cash flow
Fiscal yearFY 2025 Dec 31, 2025FY 2024 Dec 31, 2024FY 2023 Dec 31, 2023FY 2022 Dec 31, 2022FY 2021 Dec 31, 2021
-27.79M-19.15M-18.09M-17.35M-14.30M
2.05M-37.00M11.66M-16.01M0
108.46M103.48M8.41M-204.77K41.09M
-13.40K0-14.24K-243.25K0
82.73M47.33M1.98M-33.56M26.80M